Welcome to the HER2-Targeted Therapies Summit

As the HER2 field widens into new diseases and modalities, the 3rd HER2 Targeted Therapies Summit returns as the community touchpoint for all HER2 experts in preclinical, clinical, and strategic disciplines.

With dedicated sessions on HER2 expressing non-breast tumors, clinical trial stratification (especially in disease agnostic studies), managing toxicities in various tumor types or rationally selecting your ideal combination partner from the arsenal of immunotherapeutic and ADC compounds on show – this is one meeting for the whole HER2 team.

No matter what stage of development you're focusing on, don’t miss your chance to learn from the expertise and experience of the current industry leaders including: